|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HADHB |
Gene summary for HADHB |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HADHB | Gene ID | 3032 |
| Gene name | hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta | |
| Gene Alias | ECHB | |
| Cytomap | 2p23.3 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | P55084 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3032 | HADHB | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.97e-07 | 2.84e-01 | 0.0155 |
| 3032 | HADHB | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.57e-09 | 7.68e-01 | -0.0811 |
| 3032 | HADHB | HTA11_78_2000001011 | Human | Colorectum | AD | 1.27e-07 | 7.01e-01 | -0.1088 |
| 3032 | HADHB | HTA11_347_2000001011 | Human | Colorectum | AD | 2.59e-37 | 1.02e+00 | -0.1954 |
| 3032 | HADHB | HTA11_83_2000001011 | Human | Colorectum | SER | 4.73e-04 | 5.27e-01 | -0.1526 |
| 3032 | HADHB | HTA11_696_2000001011 | Human | Colorectum | AD | 1.15e-07 | 3.94e-01 | -0.1464 |
| 3032 | HADHB | HTA11_866_2000001011 | Human | Colorectum | AD | 5.71e-06 | 3.48e-01 | -0.1001 |
| 3032 | HADHB | HTA11_1391_2000001011 | Human | Colorectum | AD | 9.22e-12 | 7.16e-01 | -0.059 |
| 3032 | HADHB | HTA11_5216_2000001011 | Human | Colorectum | SER | 3.08e-02 | 3.58e-01 | -0.1462 |
| 3032 | HADHB | HTA11_7862_2000001011 | Human | Colorectum | AD | 5.10e-05 | 5.39e-01 | -0.0179 |
| 3032 | HADHB | HTA11_866_3004761011 | Human | Colorectum | AD | 8.72e-07 | 4.25e-01 | 0.096 |
| 3032 | HADHB | HTA11_8622_2000001021 | Human | Colorectum | SER | 4.71e-02 | 2.28e-01 | 0.0528 |
| 3032 | HADHB | HTA11_10623_2000001011 | Human | Colorectum | AD | 1.35e-04 | 6.95e-01 | -0.0177 |
| 3032 | HADHB | HTA11_7696_3000711011 | Human | Colorectum | AD | 3.02e-10 | 5.60e-01 | 0.0674 |
| 3032 | HADHB | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.10e-12 | 6.14e-01 | 0.294 |
| 3032 | HADHB | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.07e-03 | 5.15e-01 | 0.281 |
| 3032 | HADHB | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.35e-10 | 5.07e-01 | 0.3859 |
| 3032 | HADHB | A015-C-203 | Human | Colorectum | FAP | 4.29e-07 | -2.62e-01 | -0.1294 |
| 3032 | HADHB | A002-C-205 | Human | Colorectum | FAP | 4.21e-05 | -2.52e-01 | -0.1236 |
| 3032 | HADHB | A015-C-006 | Human | Colorectum | FAP | 1.00e-06 | -3.16e-01 | -0.0994 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00193956 | Liver | NAFLD | fatty acid oxidation | 33/1882 | 103/18723 | 7.58e-10 | 1.53e-07 | 33 |
| GO:00442425 | Liver | NAFLD | cellular lipid catabolic process | 52/1882 | 214/18723 | 1.15e-09 | 2.17e-07 | 52 |
| GO:00344405 | Liver | NAFLD | lipid oxidation | 33/1882 | 108/18723 | 2.96e-09 | 4.56e-07 | 33 |
| GO:00302585 | Liver | NAFLD | lipid modification | 49/1882 | 212/18723 | 1.97e-08 | 2.17e-06 | 49 |
| GO:00160426 | Liver | NAFLD | lipid catabolic process | 63/1882 | 320/18723 | 1.35e-07 | 1.02e-05 | 63 |
| GO:00066356 | Liver | NAFLD | fatty acid beta-oxidation | 23/1882 | 74/18723 | 5.09e-07 | 3.07e-05 | 23 |
| GO:000663112 | Liver | Cirrhotic | fatty acid metabolic process | 165/4634 | 390/18723 | 1.29e-14 | 1.26e-12 | 165 |
| GO:004428211 | Liver | Cirrhotic | small molecule catabolic process | 151/4634 | 376/18723 | 2.20e-11 | 1.34e-09 | 151 |
| GO:001605411 | Liver | Cirrhotic | organic acid catabolic process | 104/4634 | 240/18723 | 1.91e-10 | 9.53e-09 | 104 |
| GO:004639511 | Liver | Cirrhotic | carboxylic acid catabolic process | 102/4634 | 236/18723 | 3.41e-10 | 1.63e-08 | 102 |
| GO:001939512 | Liver | Cirrhotic | fatty acid oxidation | 53/4634 | 103/18723 | 4.73e-09 | 1.88e-07 | 53 |
| GO:003444011 | Liver | Cirrhotic | lipid oxidation | 53/4634 | 108/18723 | 3.85e-08 | 1.27e-06 | 53 |
| GO:007232911 | Liver | Cirrhotic | monocarboxylic acid catabolic process | 56/4634 | 122/18723 | 2.87e-07 | 7.01e-06 | 56 |
| GO:000906211 | Liver | Cirrhotic | fatty acid catabolic process | 48/4634 | 100/18723 | 3.87e-07 | 9.13e-06 | 48 |
| GO:000663512 | Liver | Cirrhotic | fatty acid beta-oxidation | 38/4634 | 74/18723 | 7.41e-07 | 1.57e-05 | 38 |
| GO:004424212 | Liver | Cirrhotic | cellular lipid catabolic process | 82/4634 | 214/18723 | 6.91e-06 | 1.08e-04 | 82 |
| GO:001604212 | Liver | Cirrhotic | lipid catabolic process | 112/4634 | 320/18723 | 2.31e-05 | 3.03e-04 | 112 |
| GO:003025811 | Liver | Cirrhotic | lipid modification | 75/4634 | 212/18723 | 3.33e-04 | 2.87e-03 | 75 |
| GO:000663122 | Liver | HCC | fatty acid metabolic process | 238/7958 | 390/18723 | 8.24e-14 | 4.84e-12 | 238 |
| GO:004428221 | Liver | HCC | small molecule catabolic process | 225/7958 | 376/18723 | 6.50e-12 | 2.80e-10 | 225 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa00280 | Colorectum | AD | Valine, leucine and isoleucine degradation | 25/2092 | 48/8465 | 3.97e-05 | 3.41e-04 | 2.18e-04 | 25 |
| hsa00071 | Colorectum | AD | Fatty acid degradation | 20/2092 | 43/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 20 |
| hsa002801 | Colorectum | AD | Valine, leucine and isoleucine degradation | 25/2092 | 48/8465 | 3.97e-05 | 3.41e-04 | 2.18e-04 | 25 |
| hsa000711 | Colorectum | AD | Fatty acid degradation | 20/2092 | 43/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 20 |
| hsa000712 | Colorectum | SER | Fatty acid degradation | 15/1580 | 43/8465 | 8.60e-03 | 4.26e-02 | 3.09e-02 | 15 |
| hsa000713 | Colorectum | SER | Fatty acid degradation | 15/1580 | 43/8465 | 8.60e-03 | 4.26e-02 | 3.09e-02 | 15 |
| hsa002802 | Colorectum | MSS | Valine, leucine and isoleucine degradation | 21/1875 | 48/8465 | 6.73e-04 | 4.51e-03 | 2.76e-03 | 21 |
| hsa000714 | Colorectum | MSS | Fatty acid degradation | 17/1875 | 43/8465 | 7.50e-03 | 2.86e-02 | 1.75e-02 | 17 |
| hsa002803 | Colorectum | MSS | Valine, leucine and isoleucine degradation | 21/1875 | 48/8465 | 6.73e-04 | 4.51e-03 | 2.76e-03 | 21 |
| hsa000715 | Colorectum | MSS | Fatty acid degradation | 17/1875 | 43/8465 | 7.50e-03 | 2.86e-02 | 1.75e-02 | 17 |
| hsa002804 | Colorectum | FAP | Valine, leucine and isoleucine degradation | 18/1404 | 48/8465 | 3.94e-04 | 3.06e-03 | 1.86e-03 | 18 |
| hsa000716 | Colorectum | FAP | Fatty acid degradation | 15/1404 | 43/8465 | 2.73e-03 | 1.23e-02 | 7.50e-03 | 15 |
| hsa002805 | Colorectum | FAP | Valine, leucine and isoleucine degradation | 18/1404 | 48/8465 | 3.94e-04 | 3.06e-03 | 1.86e-03 | 18 |
| hsa000717 | Colorectum | FAP | Fatty acid degradation | 15/1404 | 43/8465 | 2.73e-03 | 1.23e-02 | 7.50e-03 | 15 |
| hsa012129 | Esophagus | ESCC | Fatty acid metabolism | 41/4205 | 57/8465 | 5.13e-04 | 1.75e-03 | 8.98e-04 | 41 |
| hsa002809 | Esophagus | ESCC | Valine, leucine and isoleucine degradation | 34/4205 | 48/8465 | 2.34e-03 | 6.54e-03 | 3.35e-03 | 34 |
| hsa0121214 | Esophagus | ESCC | Fatty acid metabolism | 41/4205 | 57/8465 | 5.13e-04 | 1.75e-03 | 8.98e-04 | 41 |
| hsa0028014 | Esophagus | ESCC | Valine, leucine and isoleucine degradation | 34/4205 | 48/8465 | 2.34e-03 | 6.54e-03 | 3.35e-03 | 34 |
| hsa002806 | Liver | NAFLD | Valine, leucine and isoleucine degradation | 20/1043 | 48/8465 | 3.03e-07 | 1.65e-05 | 1.33e-05 | 20 |
| hsa012126 | Liver | NAFLD | Fatty acid metabolism | 17/1043 | 57/8465 | 3.43e-04 | 5.93e-03 | 4.78e-03 | 17 |
| Page: 1 2 3 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HADHB | SNV | Missense_Mutation | c.1050A>T | p.Gln350His | p.Q350H | P55084 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-A8-A08T-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| HADHB | SNV | Missense_Mutation | rs780072612 | c.520N>T | p.Arg174Cys | p.R174C | P55084 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| HADHB | SNV | Missense_Mutation | c.226N>A | p.Pro76Thr | p.P76T | P55084 | protein_coding | tolerated(0.08) | benign(0.199) | TCGA-E9-A22G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| HADHB | insertion | Frame_Shift_Ins | novel | c.328_329insAAATGAA | p.Val110GlufsTer10 | p.V110Efs*10 | P55084 | protein_coding | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| HADHB | SNV | Missense_Mutation | novel | c.86C>A | p.Ser29Tyr | p.S29Y | P55084 | protein_coding | tolerated_low_confidence(0.18) | benign(0.08) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| HADHB | SNV | Missense_Mutation | rs749861331 | c.608G>A | p.Arg203Gln | p.R203Q | P55084 | protein_coding | deleterious(0.04) | possibly_damaging(0.703) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| HADHB | SNV | Missense_Mutation | c.1051N>A | p.Leu351Ile | p.L351I | P55084 | protein_coding | deleterious(0) | probably_damaging(0.96) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| HADHB | SNV | Missense_Mutation | novel | c.505N>C | p.Ser169Pro | p.S169P | P55084 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| HADHB | SNV | Missense_Mutation | novel | c.59N>T | p.Arg20Ile | p.R20I | P55084 | protein_coding | deleterious_low_confidence(0.02) | benign(0.02) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| HADHB | SNV | Missense_Mutation | c.602N>C | p.Lys201Thr | p.K201T | P55084 | protein_coding | tolerated(0.33) | benign(0.038) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |